MPLT

+ Watchlist + Portfolio

MapLight Therapeutics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.63
52-Week Range: $9.10 – $40.43
Market Cap: $545.75M
P/E (TTM): —
EPS (TTM): -6.25
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.28
PEG Ratio: —
Return on Equity: -111.55%
Return on Assets: -67.11%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 16.52
Debt/Equity: 0.01
Total Debt: $1.99M
Free Cash Flow: $-95.21M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $152.69M

MPLT Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	—	—	$0.00
Research & Development	—	—	$138.35M
Selling, General & Admin	—	—	$30.73M
Operating Expenses	—	—	$169.08M
Operating Income	—	—	-$169.08M
EBITDA	—	—	-$168.50M
Pretax Income	—	—	-$161.15M
Net Income	—	—	-$161.15M
Diluted EPS	—	-2.96	-18.56
Diluted Shares	—	26.18M	8.68M

MPLT Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	—	—	$0.00	$0.00	$0.00	$0.00
Research & Development	$20.71M	$19.79M	$26.85M	$27.09M	$64.62M	$53.68M	$53.44M
Selling, General & Admin	$2.06M	—	—	$4.40M	$18.75M	$10.82M	$10.11M
Operating Expenses	$22.78M	$23.54M	$30.66M	$31.50M	$83.38M	$64.50M	$63.55M
Operating Income	-$22.78M	-$23.54M	-$30.66M	-$31.50M	-$83.38M	-$64.50M	-$63.55M
EBITDA	-$22.58M	-$23.38M	-$30.53M	-$31.36M	-$83.24M	-$64.34M	-$63.40M
Pretax Income	-$21.23M	-$22.34M	-$29.84M	-$29.42M	-$79.55M	-$60.67M	-$60.19M
Net Income	-$21.23M	-$22.34M	-$29.84M	-$29.42M	-$79.55M	-$60.67M	-$60.19M
Diluted EPS	—	-0.54	-0.72	-0.71	-2.47	-1.34	-1.32
Diluted Shares	—	—	41.43M	41.43M	32.15M	45.21M	45.43M

MPLT Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	—	—	—	$64.15M	$46.73M	$55.71M	$71.63M
Current Assets	—	—	—	$245.31M	$324.67M	$327.23M	$318.79M
Total Assets	—	—	—	$257.22M	$479.51M	$418.79M	$368.35M
Current Liabilities	—	—	—	$18.56M	$16.23M	$14.28M	$19.29M
Total Debt	—	—	—	$6.01M	$5.80M	$5.59M	$1.99M
Total Liabilities	$18.57M	$20.36M	$20.36M	$23.71M	$21.14M	$18.95M	$20.05M
Retained Earnings	—	—	—	-$280.97M	-$360.52M	-$421.19M	-$481.38M
Shareholders' Equity	$93.00M	$63.76M	$63.76M	$233.52M	$458.37M	$399.83M	$348.30M
Working Capital	—	—	—	$226.74M	$308.44M	$312.94M	$299.49M

MPLT Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$21.49M	—	—	-$31.79M	-$46.83M	-$51.18M	-$44.87M
Capital Expenditure	-$106.00K	—	—	-$31.00K	-$376.00K	-$24.00K	-$22.00K
Free Cash Flow	-$21.59M	—	—	-$31.82M	-$47.20M	-$51.20M	-$44.89M
Depreciation & Amortisation	$194.00K	—	—	$136.00K	$140.00K	$162.00K	$147.00K
Stock-Based Compensation	$214.00K	—	—	$125.00K	$35.52M	$9.64M	$8.63M
Investing Cash Flow	$32.39M	—	—	-$135.59M	-$242.55M	$67.01M	$60.70M
Financing Cash Flow	$5.00K	—	—	$198.06M	$271.96M	-$6.85M	$92.00K
Net Change in Cash	$10.91M	—	—	$30.68M	-$17.42M	$8.98M	$15.93M

Market Snapshot

About

Clinical-stage biopharmaceutical company developing novel therapies for neuroscience and rare diseases. Pipeline targets mechanisms including cellular plasticity and neurodegeneration. Focus on conditions with high unmet medical need and limited treatment options.